Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
S

Sodium Zirconium Cyclosilicate

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

No

Subsidy Information and Financing Scheme

No

Active ingredient: Zirconium Compounds

General information

Subsidy Information and Financing Scheme

Not Applicable

Drug Guidance for Subsidy

06/02/2026 Sodium zirconium cyclosilicate for treating hyperkalaemia

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Sodium zirconium cyclosilicate 5 g powder for oral suspension for the treatment of chronic hyperkalaemia in patients with chronic kidney disease Stage 3b to 5 (nondialysis dependent):

    • who have experienced at least 2 episodes of hyperkalaemia (defined as serum potassium levels of at least 5.5 mmol/L) in the past 12 months, and

    • who are receiving treatment with a renin-angiotensin-aldosterone system (RAAS) inhibitor, or who are indicated for treatment with a RAAS inhibitor but unable to tolerate it due to hyperkalaemia.

Funding status

[R] Sodium zirconium cyclosilicate 5 g powder for oral suspension is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.

[NR] MAF assistance does not apply to sodium zirconium cyclosilicate 10 g powder for oral suspension.

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Powder, For Suspension 5 g/sachet

  1. Alexandra Hospital

  2. Changi General Hospital

  3. National Heart Centre

  4. Ng Teng Fong General Hospital

  5. National University Hospital

  6. Sengkang General Hospital

  7. Singapore General Hospital

  8. Tan Tock Seng Hospital

Powder, For Suspension 10 g/sachet

  1. Alexandra Hospital

  2. National University Hospital

  3. Sengkang General Hospital

  4. Singapore General Hospital

  5. Tan Tock Seng Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information.

Oral

* Clinical information is available for this product.

Back to top